Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Aura Biosciences from “sell” to “hold.” Analyst views remain mixed, but MarketBeat reports an average “Moderate Buy” rating and a consensus price target of $17.50.
• Aura reported a quarterly loss of $0.29 per share, beating analyst expectations for a $0.37 loss. Analysts expect a full-year loss of $1.48 per share.
• The stock opened at $7.11, within its 12-month range of $4.73 to $9.53; institutional investors own 96.75% of its shares.

Aura Biosciences (NASDAQ:AURA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently commented on the company. Citigroup reiterated a "market outperform" rating on shares of Aura Biosciences in a research report on Tuesday. HC Wainwright lowered their price objective on Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Aura Biosciences in a research note on Monday, October 12th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aura Biosciences has an average rating of "Moderate Buy" and a consensus target price of $17.50.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $7.11 on Friday. Aura Biosciences has a twelve month low of $4.73 and a twelve month high of $9.53. The firm has a 50-day simple moving average of $6.54 and a 200 day simple moving average of $6.77.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. As a group, sell-side analysts expect that Aura Biosciences will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Aura Biosciences during the second quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aura Biosciences in the 3rd quarter valued at approximately $33,000. Parallel Advisors LLC grew its stake in shares of Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock valued at $38,000 after purchasing an additional 3,206 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Aura Biosciences in the 2nd quarter worth approximately $54,000. Finally, ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the 3rd quarter worth approximately $68,000. Institutional investors own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.